Developing a new 3D printing technology for making advanced vaccines against influenza and other infectious diseases.
A Novel First-in-class 3D Printing Technology for Advanced Manufacturing of Complex Vaccine Formulations against Influenza and Emerging Infectious Diseases
This study is exploring a new way to use 3D printing to make vaccines, especially for flu and other infectious diseases, by using yeast to produce the proteins needed for these vaccines more easily and affordably, so we can respond better to health needs around the world.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Mississippi NIH-funded |
| Lab location | 1 site (University, United States) |
| Project ID | NIH-11046367 on NIH RePORTER |
What this research studies
This research focuses on creating a novel 3D printing technology to manufacture complex vaccine formulations, particularly targeting influenza and emerging infectious diseases. By utilizing recombinant DNA technology, the project aims to produce recombinant protein subunit vaccines more efficiently and cost-effectively. The approach involves using yeast expression systems to generate high quantities of the necessary proteins, which can then be purified and formulated into vaccines. This innovative method seeks to address the current limitations in vaccine production processes, making them more flexible and responsive to global health needs.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals at risk for influenza and other emerging infectious diseases, particularly during outbreaks.
Not a fit: Patients who are not at risk for infectious diseases or those who have contraindications to vaccination may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more efficient vaccine production, improving public health responses to infectious disease outbreaks.
How similar studies have performed: While the approach of using 3D printing for vaccine production is innovative, similar technologies in recombinant protein production have shown promise in other contexts.
Where this research is happening
University, United States
- University of Mississippi — University, United States (Active)
Researchers
- Principal investigator: Maniruzzaman, Mohammed — University of Mississippi
- Study coordinator: Maniruzzaman, Mohammed
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.